Global Oncology Molecular Diagnostic Market Size Likely to Surpass at a CAGR of 11.49% By 2034

Global Oncology Molecular Diagnostic Market size was valued at USD 3.02 Billion in 2025 and is expected to reach USD 11.49 Billion by 2034, at a CAGR of 11.49% during the forecast period 2025 – 2034.

Oncology Molecular Diagnostic Market Overview

Oncology molecular diagnostics can identify cancer cells by examining their biological chemicals. Multiple assays exist for detecting and quantifying specific genetic sequences in DNA, RNA, and cell proteins from blood, saliva, and tumor tissue samples.

Oncology molecular diagnostics support swift analysis and details, which is sports used in individualized medicine for cancer therapy. Such diagnostics technologies can be utilized in clinical and point-of-care (POC) tests to diagnose cancer early. They are also used in blood banks to test donated blood for infections and infectious diseases.

Oncology molecular diagnostics can identify their presence by studying the biological chemicals in cancer cells. Several assays are applied to identify and quantify specific sequences of DNA, RNA, and cellular proteins in blood, saliva, and tumor tissue specimens.

Oncology molecular diagnostics are helpful in rapid analysis and give specific information, which is then applied in personalized cancer therapy. Some of these diagnostics technologies can be extended to clinical and point-of-care (POC) tests to facilitate early cancer detection. They may additionally be used in blood banks to screen for infections and infectious diseases in blood donations.

The high price of molecular diagnostic assays is a primary obstacle to the oncology molecular diagnostics market’s growth. In oncological diagnosis, the expense of molecular diagnostic tests per diagnostic test is relatively high and varies with therapy type.

For instance, the price of a molecular diagnostic test for monotherapy for non-small cell lung cancer is between about $11,000 and $20,000 a month, and with combination therapy, these prices are predicted to rise even further. The high cost of molecular diagnostic tests is projected to bridle the oncology molecular diagnostics market.

The rising prevalence of point-of-care oncology treatment, the rising demand for minimally invasive diagnostic procedures, the increase in biomarker identification, and the advancement in molecular techniques are the dominant and major factors that will, as expected, increase the growth of the oncology molecular diagnostic market in the appropriate forecast period.

However, on the contrary, increasing number of technological innovations coupled with increasing healthcare spending and demand for diagnostics procedure efficient and effective solutions are expected to create a plethora of opportunities thereby aiding the growth of the oncology molecular diagnostic market.

The reagent segment is dominating the market with the highest share during the forecast period as reagents are widely used in cancer research and diagnostics. Due to the increasing demand for rapid and accurate diagnostics devices, the market for instruments has shown significant growth potential during the forecast period.

The segment is projected to grow owing to the comparatively high cost of these goods and increasing market penetration of instrument manufacturers in Asia-Pacific and Latin America, along with the continuously developing healthcare infrastructure there.

The North American the market had the largest market share in 2023. All these factors of North America, such as developed healthcare infrastructure in the United States and Canada and the presence of several national reference laboratories, facilitate easy access to high-tech technologically advanced instruments.

The Asia Pacific market is anticipated to witness the fastest CAGR of 16% during the forecast period. An increasing trend of cancer in low- and middle-income populations is attributed to an ageing population and lifestyle modification associated with economic development and epidemiologic transition in the Asia Pacific region.

India, China, and Australia show great promise in this sector because of their growing economies and gigantic unmet medical needs. The demand for oncology molecular diagnostic devices in China will rise at a CAGR of 9% over the assessment period. Also, in Australia, sales of molecular diagnostic kits are expected to boom over the next decade.

Report Scope

CMI has comprehensively analyzed the Global Oncology Molecular Diagnostic market. The driving forces, restraints, challenges, opportunities, and key trends have been explained in depth to depict a deep scenario of the market. Segment-wise market size and market share during the forecast period are duly addressed to portray the probable picture of this Global Oncology Molecular Diagnostic industry.

The competitive landscape includes key innovators, after-market service providers, market giants, and niche players, which are studied and analyzed extensively for their strengths and weaknesses as value addition prospects. In addition, this report covers key players’ profiling, market shares, mergers and acquisitions, consequent market fragmentation, new trends, and dynamics in partnerships.

List of the prominent players in the Oncology Molecular Diagnostic Market:

• Guardant Health
• Exact Sciences Corp.
• Natera
• NeoGenomics Laboratories Inc.
• Cepheid
• Fujirebio
• Grail Inc.
• Roche Diagnostics
• Illumina Inc.
• Thermo Fisher Scientific
• QIAGEN
• Abbott Laboratories
• Agilent Technologies
• Bio-Rad Laboratories
• Hologic Inc.
• Myriad Genetics
• Foundation Medicine
• Invitae Corporation
• Sysmex Corporation
• Biocartis
• Others

The Oncology Molecular Diagnostic Market is segmented as follows:

By Type

• Breast Cancer
• Prostate Cancer
• Colorectal Cancer
• Cervical Cancer
• Liver Cancer
• Lung Cancer
• Blood Cancer
• Kidney Cancer
• Other Cancer

By Product

• Instruments
• Reagents
• Others

By Technology

• PCR
• In Situ Hybridization
• INAAT
• Chips and Microarrays
• Mass Spectrometry
• Sequencing
• TMA
• Others

Regional Coverage:

North America

• U.S.
• Canada
• Mexico
• Rest of North America

Europe

• Germany
• France
• U.K.
• Russia
• Italy
• Spain
• Netherlands
• Rest of Europe

Asia Pacific

• China
• Japan
• India
• New Zealand
• Australia
• South Korea
• Taiwan
• Rest of Asia Pacific

The Middle East & Africa

• Saudi Arabia
• UAE
• Egypt
• Kuwait
• South Africa
• Rest of the Middle East & Africa

Latin America

• Brazil
• Argentina
• Rest of Latin America